SAN FRANCISCO, March 23, 2010 (GLOBE NEWSWIRE) -- YesDTC Holdings, Inc. (OTCBB:YESD), a direct-to-consumer global distributor and marketer of consumer goods and products, announced today the Company has acquired the rights to the AllayTM Menstrual Pain Therapy product from BioElectronics Corp. (Pink Sheets:BIEL) for distribution in Japan. Allay is a new drug-free product that effectively treats the pain and discomfort often associated with menstruation. The product has a soft, hypoallergenic and biodegradable cover that tucks comfortably and discreetly into clothing and features a wafer-thin microchip that pulses gentle, therapeutic energy waves to reduce inflammation and alleviate painful menstrual cramping.
Under the terms of the arrangement, YesDTC will hold full television, direct-to-consumer and retail distribution rights to consumers in Japan, which represents a significant opportunity for the Company. YesDTC plans to initially launch distribution through direct response television advertising and is currently formulating plans for retail launch.
"We are very excited about the prospects the AllayTM Menstrual Pain Therapy brand faces in Japan. Cramping and pain are common problems for many women during their menstrual period and can last for several days. A recent study of women using the Allaypatch reported over 77% achieving either complete elimination or reduction of their typical menstrual pain symptoms," commented Joe Noel, CEO of YesDTC Holdings, Inc. "Importantly, the majority of women who use this product have been able to greatly reduce the amount of over-the-counter pain medications they take and with more and more news out about the harmful side effects of nonprescription drugs, many women are turning to the Allay patch as a safer, more effective period relief solution," said Noel.
"We are looking forward to working with our product partners at BioElectronics to launch distribution into this very sizable and significant market for Allay," said Joe Noel, adding "To effectively address the Japanese market, we are aligning ourselves with some of the most successful marketers within the direct response television and retailing marketplaces with plans to enter this market very quickly. Furthermore, the initial responses we have received to the drug-free nature of this product are exciting and we believe the Japanese consumer, who is much more accustomed and accepting of bioelectric therapies, will be very receptive to the Allay Menstrual Pain Therapy Patch."
About YesDTC Holdings, Inc.
YesDTC Holdings, Inc. is a direct-to-consumer marketing company specializing in direct response television (DRTV), Internet and retail marketing programs. The Company brings a unique set of skills to this marketplace. YesDTC combines both creative talents and financial acumen to create a total package for direct-to-consumer marketing programs. The Company has formed a strategic partnership with Schulberg Media Works (SMW), a pioneering firm in the direct-to-consumer space. SMW's track record is impressive with nearly $1.0 billion in revenues and a strong track record of industry awards. SMW campaigns include Tempur-Pedic, Guthy-Renker, Sony, 24-Hour Fitness, Rhino Records, HarperCollins and PureSleep, among many others.
About BioElectronics Corporation
BioElectronics Corporation is the maker of ActiPatch(R) Therapy, RecoveryRx(TM) Devices, HealFast(TM) Therapy (http://www.healfasttherapy.com/) and the Allay(TM) family of inexpensive, disposable drug-free anti-inflammatory devices. For more information please see http://www.BioElectronicsCorp.com.
Forward-Looking Statements
Certain statements in this press release may constitute "forward-looking statements" that involve risks and uncertainties. These include statements about our expectations, plans, objectives, assumptions or future events. You should not place undue reliance on these forward-looking statements. Information concerning factors that could cause our actual results to differ materially from these forward-looking statements can be found in our periodic reports filed with the Securities and Exchange Commission. We undertake no obligation to publicly release revisions to these forward-looking statements to reflect future events or circumstances or reflect the occurrence of unanticipated events.